Published in Med J Aust on November 05, 2001
Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications. Clin Microbiol Rev (2010) 4.76
Evolution of multidrug resistance during Staphylococcus aureus infection involves mutation of the essential two component regulator WalKR. PLoS Pathog (2011) 2.15
Comparison of detection methods for heteroresistant vancomycin-intermediate Staphylococcus aureus, with the population analysis profile method as the reference method. J Clin Microbiol (2010) 1.57
Prevalence and characteristics of heteroresistant vancomycin-intermediate Staphylococcus aureus bacteremia in a tertiary care center. J Clin Microbiol (2007) 1.44
Investigation of reduced susceptibility to glycopeptides among methicillin-resistant Staphylococcus aureus isolates from patients in Ireland and evaluation of agar screening methods for detection of heterogeneously glycopeptide-intermediate S. aureus. J Clin Microbiol (2007) 1.20
Performance of various testing methodologies for detection of heteroresistant vancomycin-intermediate Staphylococcus aureus in bloodstream isolates. J Clin Microbiol (2011) 1.16
Low-level vancomycin resistance in Staphylococcus aureus--an Australian perspective. Eur J Clin Microbiol Infect Dis (2005) 1.16
Daptomycin in bone and joint infections: a review of the literature. Arch Orthop Trauma Surg (2008) 1.11
Clinical features and treatment outcomes of vancomycin-intermediate Staphylococcus aureus (VISA) and heteroresistant vancomycin-intermediate Staphylococcus aureus (hVISA) in a tertiary care institution in Singapore. Eur J Clin Microbiol Infect Dis (2009) 1.10
Evidence for reduction in breakpoints used to determine vancomycin susceptibility in Staphylococcus aureus. Antimicrob Agents Chemother (2005) 1.10
Mechanism of reduced vancomycin susceptibility conferred by walK mutation in community-acquired methicillin-resistant Staphylococcus aureus strain MW2. Antimicrob Agents Chemother (2014) 0.82
First detection of an invasive Staphylococcus aureus strain (D958) with reduced susceptibility to glycopeptides in Saudi Arabia. J Clin Microbiol (2010) 0.80
Vancomycin tolerant, methicillin-resistant Staphylococcus aureus reveals the effects of vancomycin on cell wall thickening. PLoS One (2015) 0.77
Laboratory detection and investigation of reduced susceptibility to vancomycin in oxacillin-resistant Staphylococcus aureus. Eur J Clin Microbiol Infect Dis (2003) 0.77
Effects of aggregate and individual antibiotic exposure on vancomycin MICs for Staphylococcus aureus isolates recovered from pediatric patients. J Clin Microbiol (2013) 0.76
Development of a PCR assay for rapid diagnosis of Mycobacterium ulcerans infection. J Clin Microbiol (1997) 3.96
Identification and characterization of IS2404 and IS2606: two distinct repeated sequences for detection of Mycobacterium ulcerans by PCR. J Clin Microbiol (1999) 3.96
Detection of Mycobacterium ulcerans in environmental samples during an outbreak of ulcerative disease. Appl Environ Microbiol (1997) 2.88
Mycobacterium ulcerans in wild animals. Rev Sci Tech (2001) 2.84
Comparative genetic analysis of Mycobacterium ulcerans and Mycobacterium marinum reveals evidence of recent divergence. J Bacteriol (2000) 2.59
A simple PCR method for rapid genotype analysis of Mycobacterium ulcerans. J Clin Microbiol (2000) 2.43
The etiology of community-acquired pneumonia in Australia: why penicillin plus doxycycline or a macrolide is the most appropriate therapy. Clin Infect Dis (2008) 2.39
Postmarketing surveillance: strengths and limitations. The flucloxacillin-dicloxacillin story. Med J Aust (1999) 2.16
Identification of Mycobacterium ulcerans in the environment from regions in Southeast Australia in which it is endemic with sequence capture-PCR. Appl Environ Microbiol (2000) 2.14
Universal precautions: attitudes of Australian and New Zealand anaesthetists. Med J Aust (1997) 2.01
Tuberculin-purified protein derivative-, MPT-64-, and ESAT-6-stimulated gamma interferon responses in medical students before and after Mycobacterium bovis BCG vaccination and in patients with tuberculosis. Clin Diagn Lab Immunol (1999) 1.97
Malaria acquired in Bali. Med J Aust (1995) 1.93
Outcome of a screening program for vancomycin-resistant enterococci in a hospital in Victoria. Med J Aust (1999) 1.91
Direct detection of vanB2 using the Roche LightCycler vanA/B detection assay to indicate vancomycin-resistant enterococcal carriage--sensitive but not specific. J Antimicrob Chemother (2007) 1.88
A large localized outbreak of Mycobacterium ulcerans infection on a temperate southern Australian island. Epidemiol Infect (1997) 1.82
Immune response to infection with Mycobacterium ulcerans. Infect Immun (2001) 1.82
Comparison of three PCR primer sets for identification of vanB gene carriage in feces and correlation with carriage of vancomycin-resistant enterococci: interference by vanB-containing anaerobic bacilli. Antimicrob Agents Chemother (2005) 1.81
Empowerment: an idea whose time has come in diabetes education. Diabetes Educ (1991) 1.76
Cardiac teratogenesis of halogenated hydrocarbon-contaminated drinking water. J Am Coll Cardiol (1993) 1.68
Assessing the duration of mandibular soft tissue anesthesia. J Am Dent Assoc (1995) 1.66
Enterococcal vanB resistance locus in anaerobic bacteria in human faeces. Lancet (2001) 1.60
Is fosfomycin a potential treatment alternative for multidrug-resistant gram-negative prostatitis? Clin Infect Dis (2013) 1.60
Molecular characterization of vanB elements in naturally occurring gut anaerobes. Antimicrob Agents Chemother (2005) 1.58
Classification of medically important clostridia using restriction endonuclease site differences of PCR-amplified 16S rDNA. J Gen Microbiol (1991) 1.57
Prospective comparison of the clinical impacts of heterogeneous vancomycin-intermediate methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-susceptible MRSA. Antimicrob Agents Chemother (2009) 1.50
High-dose oral acyclovir reduces the incidence of cytomegalovirus infection in liver transplant recipients. J Infect Dis (1993) 1.45
Clinical manifestations and outcome of Haemophilus influenzae type b disease. J Paediatr Child Health (1995) 1.44
A comparison of two dosing regimens of zidovudine in Thai adults with early symptomatic HIV infection. Conducting clinical HIV trials in South-East Asia. Aust N Z J Med (2000) 1.42
Mycobacterium ulcerans infection on Phillip Island, Victoria. Med J Aust (1995) 1.42
Nocardia veterana sp. nov., isolated from human bronchial lavage. Int J Syst Evol Microbiol (2001) 1.40
HIV in the suburbs. Med J Aust (1993) 1.38
Detection of Clostridium difficile enterotoxin gene in clinical specimens by the polymerase chain reaction. J Med Microbiol (1993) 1.38
Genomic approaches to typing, taxonomy and evolution of bacterial isolates. Int J Syst Evol Microbiol (2001) 1.37
A meta-analysis of studies on the safety and efficacy of aminoglycosides given either once daily or as divided doses. J Antimicrob Chemother (1996) 1.36
In vitro inhibition of Helicobacter pylori NCTC 11637 by organic acids and lactic acid bacteria. J Appl Bacteriol (1995) 1.34
The role of social and cognitive processes in children's adjustment to community violence. J Consult Clin Psychol (1998) 1.33
Association between severe pandemic 2009 influenza A (H1N1) virus infection and immunoglobulin G(2) subclass deficiency. Clin Infect Dis (2010) 1.32
Tipranavir (PNU-140690): a potent, orally bioavailable nonpeptidic HIV protease inhibitor of the 5,6-dihydro-4-hydroxy-2-pyrone sulfonamide class. J Med Chem (1998) 1.29
High rates of fecal carriage of nonenterococcal vanB in both children and adults. Antimicrob Agents Chemother (2008) 1.29
Mycobacterium ulcerans--a mini-review. J Med Microbiol (1999) 1.27
A quantitative assessment of the efficacy of surgical and N95 masks to filter influenza virus in patients with acute influenza infection. Clin Infect Dis (2009) 1.25
Random amplified polymorphic DNA and plasmid analyses used in investigation of an outbreak of multiresistant Klebsiella pneumoniae. J Clin Microbiol (1995) 1.25
Structure-based design of HIV protease inhibitors: sulfonamide-containing 5,6-dihydro-4-hydroxy-2-pyrones as non-peptidic inhibitors. J Med Chem (1996) 1.24
In vitro activity of sparfloxacin (AT-4140, CI-978, PD 131501), a new quinolone antimicrobial agent. Diagn Microbiol Infect Dis (1991) 1.19
Psittacosis--a review of 135 cases. Med J Aust (1988) 1.17
Quasiparticle spectra, charge-density waves, superconductivity, and electron-phonon coupling in 2H-NbSe2. Phys Rev Lett (2004) 1.16
Rapid identification of mycobacteria using gas liquid chromatography. Pathology (1985) 1.16
Low-level vancomycin resistance in Staphylococcus aureus--an Australian perspective. Eur J Clin Microbiol Infect Dis (2005) 1.16
Optimum treatment of staphylococcal infections. Drugs (1993) 1.13
Herpes simplex virus encephalitis in pediatrics: diagnosis by detection of antibodies and DNA in cerebrospinal fluid. Pediatr Infect Dis J (1993) 1.10
Comparison of the Xpert methicillin-resistant Staphylococcus aureus (MRSA) assay, BD GeneOhm MRSA assay, and culture for detection of nasal and cutaneous groin colonization by MRSA. J Clin Microbiol (2009) 1.09
Enterococcal bacteraemia: factors influencing mortality, length of stay and costs of hospitalization. Clin Microbiol Infect (2013) 1.09
Antimicrobial resistance testing of Helicobacter pylori: a comparison of Etest and disk diffusion methods. Pathology (1997) 1.09
Vancomycin vintage: my favourite DRESS. Intern Med J (2015) 1.08
Comparison of daptomycin, vancomycin, and ampicillin-gentamicin for treatment of experimental endocarditis caused by penicillin-resistant enterococci. Antimicrob Agents Chemother (1992) 1.07
It's time to move beyond trying to predict mortality using severity assessment tools in community-acquired pneumonia. Intern Med J (2014) 1.07
Structure-based design of nonpeptidic HIV protease inhibitors: the sulfonamide-substituted cyclooctylpyramones. J Med Chem (1997) 1.06
Cardiac teratogenesis of trichloroethylene and dichloroethylene in a mammalian model. J Am Coll Cardiol (1990) 1.03
Emergence of preformed Cooper pairs from the doped Mott insulating state in Bi2Sr2CaCu2O8+delta. Nature (2008) 1.00
Improved detection of vanB2-containing enterococcus faecium with vancomycin susceptibility by Etest using oxgall supplementation. J Clin Microbiol (2008) 0.99
Fecal colonization with vancomycin-resistant enterococci in Australia. Emerg Infect Dis (2000) 0.97
Assessing the risk of tuberculosis infection among healthcare workers: the Melbourne Mantoux Study. Melbourne Mantoux Study Group. Med J Aust (2001) 0.96
Smoking and varicella pneumonia. J Infect (1988) 0.95
Cardiac teratogenicity of dichloroethylene in a chick model. Pediatr Res (1992) 0.95
Respiratory symptoms and duration of residence in immigrant teenagers living in Melbourne, Australia. Arch Dis Child (1999) 0.93
Home-based treatment of cellulitis with twice-daily cefazolin. Med J Aust (1998) 0.93
Severe dapsone syndrome due to weekly maloprim. Lancet (1988) 0.93
Clostridium lavalense sp. nov., a glycopeptide-resistant species isolated from human faeces. Int J Syst Evol Microbiol (2009) 0.93
The clinical efficacy of continuous-infusion flucloxacillin in serious staphylococcal sepsis. J Antimicrob Chemother (1999) 0.93
Risk factors for adverse cutaneous reactions associated with intravenous vancomycin. J Antimicrob Chemother (1997) 0.91
DNA sequence heterogeneity in the three copies of the long 16S-23S rDNA spacer of Enterococcus faecalis isolates. Microbiology (1999) 0.90
A paired comparison of tuberculin skin test results in health care workers using 5 TU and 10 TU tuberculin. Thorax (2000) 0.90
Chronic meningitis due to herpes simplex virus in an immunocompetent host. Eur J Clin Microbiol Infect Dis (1996) 0.89
Hospital-in-the-home care: is it worth the hassle? Med J Aust (1998) 0.89
Polymicrobial septicaemia with Pseudomonas aeruginosa and Streptococcus pyogenes following traditional tattooing. J Infect (1997) 0.88
Virulence determinants in vancomycin-resistant Enterococcus faecium vanB: clonal distribution, prevalence and significance of esp and hyl in Australian patients with haematological disorders. J Hosp Infect (2008) 0.88
Genetic transfer and genome evolution in MRSA. Microbiology (2001) 0.87
The regioselective aminohydroxylation of allylic carbamates. Chem Commun (Camb) (2001) 0.86
Electronic estimations of renal function are inaccurate in solid-organ transplant recipients and can result in significant underdosing of prophylactic valganciclovir. Antimicrob Agents Chemother (2013) 0.86
Maintenance of soft tissue changes after rigid versus wire fixation for mandibular advancement, with and without genioplasty. Oral Surg Oral Med Oral Pathol Oral Radiol Endod (2001) 0.86
Discovery, synthesis, and bioactivity of bis(heteroaryl)piperazines. 1. A novel class of non-nucleoside HIV-1 reverse transcriptase inhibitors. J Med Chem (1994) 0.85
An Australian isolate of Mycobacterium shimoidei. Pathology (1998) 0.85
Coherence incoherence and dimensional crossover in layered strongly correlated metals. Nature (2002) 0.85
Isoniazid toxicity in health care workers. Clin Infect Dis (1999) 0.83
Reconstructed Fermi surface of underdoped Bi2Sr2CaCu2O(8+δ) cuprate superconductors. Phys Rev Lett (2011) 0.83
Neurological complications of chlamydial infections: case report and review. Clin Infect Dis (1997) 0.83
Rural Stroke Caregivers: A Qualitative Study of the Positive and Negative Response to the Caregiver Role. Top Stroke Rehabil (1998) 0.82
Trichloroethylene, trichloroacetic acid, and dichloroacetic acid: do they affect fetal rat heart development? Int J Toxicol (2001) 0.82
Structure-based design of HIV protease inhibitors: 5,6-dihydro-4-hydroxy-2-pyrones as effective, nonpeptidic inhibitors. J Med Chem (1996) 0.81
Inducible resistance to clindamycin in Staphylococcus aureus: validation of Vitek-2 against CLSI D-test. Pathology (2013) 0.81
The prevalence of fecal colonization with VRE among residents of long-term-care facilities in Melbourne, Australia. Infect Control Hosp Epidemiol (2001) 0.81
Significant reduction in vancomycin-resistant enterococcus colonization and bacteraemia after introduction of a bleach-based cleaning-disinfection programme. J Hosp Infect (2012) 0.81